Nelivaptan is a potent and selective vasopressin V1b receptor antagonist that was studied in a total of 19 clinical trials in Phase 1 and Phase 2 as a potential treatment for MDD and generalized anxiety disorder (GAD) (11). Here, AVPR1B is linked to generalized anxiety disorder.